Akari Therapeutics (AKTX) Cash from Financing Activities (2014 - 2026)

Akari Therapeutics (AKTX) has reported Cash from Financing Activities for 8 consecutive years, with $53000.0 the latest figure, recorded in Q1 2026.

• Quarterly Cash from Financing Activities fell 97.52% year-over-year to $53000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $11.1 million (down 4.45% YoY) and the FY2025 annual result came in at $13.2 million, up 19.87% from the prior year.
• Cash from Financing Activities declined to $53000.0 in Q1 2026 per AKTX's latest filing, from $5.8 million in the prior quarter.
• Over the last five years, Cash from Financing Activities for AKTX reached as high as $7.8 million in Q2 2024 and fell as low as -$443000.0 in Q3 2024.
• A 4-year average of $2.6 million and a median of $2.1 million in 2024 frame the typical range for Cash from Financing Activities.
• Annual changes were most pronounced in 2024 — Cash from Financing Activities surged 2567.7% — and 2026, when it plunged 97.52%.
• Year by year, Cash from Financing Activities stood at $3.5 million in 2023, then sank by 38.75% to $2.2 million in 2024, then soared by 167.41% to $5.8 million in 2025, then slumped by 99.08% to $53000.0 in 2026.
• According to Business Quant data, Cash from Financing Activities over the past three periods registered $53000.0, $5.8 million, and $1.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.